检索结果 - Linqin Wang

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019

    Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019 由 Linghui Zhou, Qin Yu, Guoqing Wei, Linqin Wang, Yue Huang, Kejia Hu, Yongxian Hu, He Huang

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

    New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia 由 Linqin Wang, Ruimin Hong, Linghui Zhou, Fang Ni, Mingming Zhang, Houli Zhao, Wenjun Wu, Yiyun Wang, Shuyi Ding, Alex H. Chang, Yongxian Hu, He Huang

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

    Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refracto... 由 Qiqi Zhang, Cheng Zu, Ruirui Jing, Youqin Feng, Yanlei Zhang, Mingming Zhang, Yuqi Lv, Jiazhen Cui, Linhui Zhou, Ye Meng, Linqin Wang, Zenan Cen, Alex H. Chang, Yongxian Hu, He Huang

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma

    Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma 由 Ruimin Hong, Elaine Tan Su Yin, Linqin Wang, Xin Zhao, Linghui Zhou, Guangfa Wang, Mingming Zhang, Houli Zhao, Guoqing Wei, Yiyun Wang, Wenjun Wu, Yafei Zhang, Fang Ni, Yongxian Hu, He Huang, Kui Zhao

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

    Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy 由 Mingming Zhang, Linghui Zhou, Houli Zhao, Yanlei Zhang, Guoqing Wei, Ruimin Hong, Wenjun Wu, Huijun Xu, Linqin Wang, Fang Ni, Jiazhen Cui, Shuixiu Peng, Chih-Hua Huang, Alex H. Chang, Yongxian Hu, He Huang

    出版 2021
    获取全文
    Carta
    加到收藏夹
    Saved in:
  6. 6
    CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies

    CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies 由 Yongxian Hu, Jingjing Li, Fang Ni, Zhongli Yang, Xiaohua Gui, Zhiwei Bao, Houli Zhao, Guoqing Wei, Yiyun Wang, Mingming Zhang, Ruimin Hong, Linqin Wang, Wenjun Wu, Mohamad Mohty, Arnon Nagler, Alex H. Chang, Marcel R.M. van den Brink, Ming D. Li, He Huang

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: